hotspot -WSS

hotspot

author：hotspot 2025-10-01 00:58:09 - browse：3327

Kevin Sayer, CEO of Dexcom Dexcom

For years, diabetes tech company Dexcom has been striving to get its continuous glucose monitors into the hands of type 2 diabetes patients. Last week at the American Diabetes Association’s conference, the company unveiled plans for software built entirely for these patients, including ones who don’t take insulin.

“We’ve been so focused on things that match the needs of somebody who manages diabetes every minute of every day, and insulin delivery,” Kevin Sayer, CEO of Dexcom, told STAT. “This new product is going to be designed to address the needs of somebody with diabetes who’s not doing that, who has type 2 diabetes and is on other drugs.”

Continuous glucose monitoring is already well-established among people with type 1 diabetes, who rely on constant insulin therapy. The technology, which helps patients noninvasively monitor their blood sugar levels and control their insulin pump in real time, has grown rapidly in use over the years, culminating in a $5 billion market.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Stroke deaths set to near 10 million globally by 2050

explore

WSS

Sana to lay off nearly a third of staff, de

Second xenotransplant done with gene

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Stroke deaths set to near 10 million globally by 2050

Lasker Awards 2023: Winners in biomedical research

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

focus

hotspot

Wikipedia

Walensky prepares to leave CDC — and Congress — behind

What to expect at HLTH 2023, the health care industry conference

What does generative AI mean for health care? We asked experts

CommonSpirit Health keeps growing, even as it loses money

Affirmative action in medical school literally saved lives

Phenylephrine and the overlooked value of the placebo effect

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Biotech lab space demand falls sharply

Medical records are filled with copy

Sana to lay off nearly a third of staff, de

knowledge

Why Charlie Gard's case is so disturbing to Americans

FDA panel to weigh approval of NurOwn, controversial ALS drug

Bill would stop addiction treatment from triggering child abuse inquiry

Second xenotransplant done with gene

Second xenotransplant done with gene

The future of health care in the House

explore

focus

explore

focus